icon-folder.gif   Conference Reports for NATAP  
  EASL 2024
June 5-8, Milan, Italy
Back grey_arrow_rt.gif
Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis
  EASL 2024 June 5-8
Soek Siam Tan1, CarolineMen.trey2, Isabela Ribeiro2, Nicolas Salvadori3, Sabine Yerly4, Nicole Ngo-Giang-Huong5, Graciela Diap2. 1Hospital Selayang, Dept of Hepatology, Batu Caves, Malaysia; 2DNDi, Geneva, Switzerland; 3AMS-PHPT Research Platform, Muang, Chiang Mai, Thailand; 4Hopitaux Universitaires de Geneve, Geneve, Switzerland; 5AMS-BAT Laboratory, Muang, ChiangMai, Thailand